, Nov. 22, 2010
/PRNewswire-FirstCall/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty technology-based life science company, today announced it has signed a "Stand Still" agreement with a leading pharmaceutical company, DFB Pharmaceuticals, Inc. (DFB).
The Terms of the Agreement are being held Confidential. H. Paul Dorman, Chairman and CEO of DFB Pharmaceuticals, said "We believe BioNeutral's Ygiene and Ogiene technology may have opportunities in a number of markets, with the hospital, professional human and animal health care market as one of the most promising areas. Confirmation of materials compatibility and lack of product residue with flexible endoscopes will be a requirement for commercial development with any potential partner. This testing is expected to be completed within ninety (90) days. DFB will fund the expense to perform this confirmatory testing."
In partnership with Dr. Norman Miner, founder of MicroChem Laboratory, DFB has developed patented sterilant technology and recently developed a FDA approved, patented high level disinfectant product for the endoscopy market. North American rights to this product have been licensed to the Olympus Corporation, which is considered the gold standard of endoscopes.
Dr. Andy Kielbania, Chief Scientist of BioNeutral Group stated: "This confirmatory testing agreement with DFB Pharmaceuticals validates our commitment to providing a new level of safe antimicrobial effectiveness to the health care facility, professional human and veterinary health care market. We are looking forward to working with Dr. Norman Miner of MicroChem Labs, who is a well-known expert in the field of disinfectants and sterilants."
About DFB Pharmaceuticals
DFB Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company whose operating subsidiaries and affiliates provide branded products, quality services and innovative technologies to the global healthcare industry. Its DPT Laboratories organization is the premier contract manufacturer of pharmaceutical grade liquid and semi-solid products and works with most of the leading pharmaceutical companies. OPT has FDA compliant manufacturing facilities in New Jersey and Texas. Through its affiliate Phyton Biotech GmbH, they also have manufacturing facilities in Germany where they produce a leading oncology API through an award winning environmentally friendly process. Its HealthPoint division alone employs approximately 250 individuals, including a sophisticated field sales force of approximately 150 individuals calling on the U.S. hospital market. The Company enjoys an excellent reputation as a leader in the wound care field. DFB Pharma has developed a number of novel technologies in the area of infection prevention, including the world's first brush-free surgeon's scrub.
For more information on DFB Pharmaceuticals, Inc., see www.dfb.com
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com or read our blog at www.bioneutralblog.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene and are not yet available for sale in the UnitedStates.
SOURCE BioNeutral Group, Inc.